LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

LENZ Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$3.30+0.03 (+0.92%)

Close on Oct 19, 2026

Market cap: $103.54M
P/E (TTM): –
Dividend yield: –

LENZ Therapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	19	0	–	–	–	–
Cost of Revenue	0.42	0	–	–	–	–
Gross Profit	19	0	–	–	–	–
Research & Development	19	30	60	73	38	9.12
Selling, General & Admin	91	29	13	–	–	–
General & Administrative	–	–	41	33	23	4.38
Advertising Expenses	8.00	0	–	–	–	–
Operating Expenses	–	59	72	106	60	14
Total Costs & Expenses	110	59	–	–	–	–
Operating Income	-91	-59	-72	-106	-60	-14
Interest & Investment Income	9.76	8.55	2.19	–	–	–
Other Non-Operating Income	9.51	8.84	2.28	4.59	-10	-55
Merger & Restructuring Charges	–	–	62	0	–	–
Asset Impairment Charges	–	–	54	0	0	0
Gain (Loss) on Investments	-0.20	1.34	–	–	–	–
Gain (Loss) on Sale of Assets	0	-0.02	0	0	–	–
Pretax Income	-82	-50	-70	–	–	–
Income Tax Expense	0.50	0.00	-0.18	0	0	0
Net Income incl. Noncontrolling Interests	–	–	-125	-101	-71	-68
Net Income	-82	-50	-70	-101	-71	-68
EPS (Basic)(per share)	-2.85	-2.34	-35.71	-53.36	-71.05	-867.97
EPS (Diluted)(per share)	-2.85	-2.34	-35.71	-53.36	-71.05	-867.97
Shares Outstanding (Basic, Weighted)(shares)	29	21	1.96	1.89	1.00	0.08
Shares Outstanding (Diluted, Weighted)(shares)	29	21	1.96	1.89	1.00	0.08
EBITDA	-91	-59	-72	-103	-60	-13

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 86.9%
Operating margin: -631.7%
Net margin: -586.7%
Return on equity, FY2025: -33.6%

Financial strength

Current ratio: 13.55
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 140.6%

Valuation

P/E ratio: –
Price to sales: 4.82
Price to book: 0.47
Dividend yield: –